Customer Publication

Genetic deletion of HPV E7 oncogene effectively regresses HPV driven oral squamous carcinoma tumour growth

Authors: D. AssisFerreira et al.

Journal: Biomedicine & Pharmacotherapy (2022)

Institution: Griffith University

Research Areas: Virus, cancer research

Cell Lines: SCC2, HEK293T cells (HPV+ OSC cell line, kidney epithelial-like cell)

Summary: The E6 and E7 are the main oncogenes that drive the carcinogenic process in the human papillomavirus (HPV)s. It is well-established that the removal of E7 dampens HPV cancer cell growth and proliferation, and this makes E7 a perfect target for HPV cancer treatment. Previous studies showed the presence of HPV E7 sensitizes both HPV-positive cervical and OSC tumors to tumor regression by inhibiting aurora kinases (AUR). In this study, authors investigated a staggering combination of aurora kinase inhibition, using AUR inhibitor, alisertib, followed by CRISPR editing of E7, to determine if this would lead to better HPV+ OSC killing. HoloMonitor M4 was used to compare cells with or without AUR inhibitor treatment.

Keywords: HoloMonitor M4, Human papillomavirus, E7, CRISPR, Oral cancer, Aurora kinase

Read the article …

Phase Holographic Imaging PHI AB
Skiffervägen 48
224 78 Lund
Sweden
+46 46 38 60 80
info@phiab.se

Phase Holographic Imaging PHI Inc.
265 Franklin Street Suite 1702
Boston, MA 02110
USA
+1 617-963-5150
info@phiab.com

Invoicing

VAT: SE556542781101
faktura@phiab.se

Securities Identification

ISIN: SE0005504636
LEI: 549300JZR79QYESM6296

HoloMonitor® is a registered trademark
Copyright © 2012-2021
Phase Holographic Imaging PHI AB

Phase Holographic Image logo in white

PHI Theme 3.12.2